DK3465214T3 - Fremgangsmåder til forudsigelse af terapeutisk fordel ved anti-cd19-terapi hos patienter - Google Patents
Fremgangsmåder til forudsigelse af terapeutisk fordel ved anti-cd19-terapi hos patienter Download PDFInfo
- Publication number
- DK3465214T3 DK3465214T3 DK17728484.1T DK17728484T DK3465214T3 DK 3465214 T3 DK3465214 T3 DK 3465214T3 DK 17728484 T DK17728484 T DK 17728484T DK 3465214 T3 DK3465214 T3 DK 3465214T3
- Authority
- DK
- Denmark
- Prior art keywords
- predicting
- therapy
- patients
- procedures
- therapeutic benefit
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16171885 | 2016-05-30 | ||
| PCT/EP2017/063045 WO2017207574A1 (en) | 2016-05-30 | 2017-05-30 | Methods for predicting therapeutic benefit of anti-cd19 therapy in patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3465214T3 true DK3465214T3 (da) | 2021-05-31 |
Family
ID=56116221
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17728484.1T DK3465214T3 (da) | 2016-05-30 | 2017-05-30 | Fremgangsmåder til forudsigelse af terapeutisk fordel ved anti-cd19-terapi hos patienter |
| DK21170716.1T DK3916392T3 (da) | 2016-05-30 | 2017-05-30 | Fremgangsmåder til at forudsige terapeutiske fordele af anti-CD19-behandlingen hos patienter |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK21170716.1T DK3916392T3 (da) | 2016-05-30 | 2017-05-30 | Fremgangsmåder til at forudsige terapeutiske fordele af anti-CD19-behandlingen hos patienter |
Country Status (26)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016311136B2 (en) | 2015-08-21 | 2022-02-17 | Incyte Corporation | Combinations and uses thereof |
| SMT202100317T1 (it) | 2016-06-27 | 2021-07-12 | Morphosys Ag | Formulazioni di anticorpi anti-cd19 |
| WO2018078123A1 (en) | 2016-10-28 | 2018-05-03 | Morphosys Ag | Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof |
| KR20200030337A (ko) | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
| CN114072424A (zh) | 2019-05-03 | 2022-02-18 | 莫佛塞斯公司 | 具有有限数量的nk细胞的患者中的抗cd19疗法 |
| WO2021084062A1 (en) * | 2019-10-31 | 2021-05-06 | Morphosys Ag | Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma |
| TW202131950A (zh) * | 2019-10-31 | 2021-09-01 | 德商莫菲西斯公司 | 依序抗ｃｄ１９療法 |
| EP4168449A1 (en) * | 2020-06-22 | 2023-04-26 | MorphoSys AG | Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirpa-cd47 innate immune checkpoint |
| AU2021391623A1 (en) * | 2020-12-04 | 2023-06-29 | Incyte Corporation | Anti-cd19 combination therapy |
| WO2026024668A1 (en) * | 2024-07-22 | 2026-01-29 | Abbott Laboratories | Method of determining a volume of a liquid in a sample |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| JP3614866B2 (ja) | 1997-06-12 | 2005-01-26 | リサーチ コーポレイション テクノロジーズ，インコーポレイティド | 人工抗体ポリペプチド |
| PT1974747E (pt) * | 1998-08-11 | 2012-09-05 | Biogen Idec Inc | Terapias de combinação para linfomas de células b compreendendo a administração de anticorpo anti-cd20 |
| JP4361273B2 (ja) | 2001-02-27 | 2009-11-11 | アメリカ合衆国 | 潜在的な血管形成阻害剤としてのサリドマイド類似体 |
| WO2005016326A2 (en) | 2003-07-11 | 2005-02-24 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Analogs of thalidomide as potential angiogenesis inhibitors |
| JP4733635B2 (ja) | 2003-07-31 | 2011-07-27 | イミューノメディクス、インコーポレイテッド | 抗ｃｄ１９抗体 |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| PT1853718E (pt) * | 2005-02-15 | 2015-11-12 | Univ Duke | Anticorpos anti-cd19 e usos em oncologia |
| WO2007002223A2 (en) | 2005-06-20 | 2007-01-04 | Medarex, Inc. | Cd19 antibodies and their uses |
| AU2006332155B2 (en) | 2005-12-30 | 2013-01-10 | Cancer Research Technology Limited | Anti-CD19 antibodies with reduced immunogenicity |
| RS53263B (sr) | 2006-08-14 | 2014-08-29 | Xencor Inc. | Optimizovana antitela usmerena na cd19 |
| US8323653B2 (en) | 2006-09-08 | 2012-12-04 | Medimmune, Llc | Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| US20100167315A1 (en) | 2006-09-13 | 2010-07-01 | Glycode | Method for investigating the response to a treatment with a monoclonal antibody |
| CA2693053C (en) | 2007-05-30 | 2021-01-05 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
| CN101903403B (zh) | 2007-10-19 | 2016-03-16 | 西雅图基因公司 | Cd19结合剂及其应用 |
| CA2753158A1 (en) | 2009-02-23 | 2010-08-26 | Glenmark Pharmaceuticals S.A. | Humanized antibodies that bind to cd19 and their uses |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
| EP2409993A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC function with improved glycosylation profile |
| EP2409712A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile |
| SG190254A1 (en) | 2010-11-15 | 2013-06-28 | Medimmune Llc | Combination therapy for b cell lymphomas |
| EP2524929A1 (en) | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| CA2841738C (en) * | 2011-08-16 | 2022-12-06 | Morphosys Ag | Combination therapy with an anti-cd19 antibody and a purine analog |
| SG10201606785UA (en) | 2011-08-16 | 2016-10-28 | Morphosys Ag | Combination therapy with an anti - cd19 antibody and a nitrogen mustard |
| EP2791165A4 (en) * | 2011-12-12 | 2015-08-05 | Pikamab Inc | PREDICTING SENSITIVITY TO ANTIBODY MAINTENANCE THERAPY |
| US20130273032A1 (en) | 2012-03-02 | 2013-10-17 | Roche Glycart Ag | Predictive biomarker for cancer treatment with adcc-enhanced antibodies |
| CA2935748A1 (en) * | 2014-02-25 | 2015-09-03 | Immunomedics, Inc. | Humanized rfb4 anti-cd22 antibody |
| EP3157553A4 (en) * | 2014-06-16 | 2018-02-28 | Xencor, Inc. | Treatment for chronic lymphocytic leukemia (cll) |
| US10969391B2 (en) | 2014-07-11 | 2021-04-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing hematological cancers |
| JP6916741B2 (ja) | 2015-05-26 | 2021-08-11 | モルフォシス・アーゲー | 抗ｃｄ１９抗体およびブルトン型チロシンキナーゼ阻害剤の組み合わせ、およびその使用 |
| AU2016311136B2 (en) | 2015-08-21 | 2022-02-17 | Incyte Corporation | Combinations and uses thereof |
| SMT202100317T1 (it) | 2016-06-27 | 2021-07-12 | Morphosys Ag | Formulazioni di anticorpi anti-cd19 |
| WO2018078123A1 (en) | 2016-10-28 | 2018-05-03 | Morphosys Ag | Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof |
| HUE063119T2 (hu) | 2017-05-31 | 2024-01-28 | Morphosys Ag | Kezelési paradigma anti-CD19 antitest és venetoclax kombinációs kezeléshez |
| KR20200030337A (ko) | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
| CN114072424A (zh) | 2019-05-03 | 2022-02-18 | 莫佛塞斯公司 | 具有有限数量的nk细胞的患者中的抗cd19疗法 |
| LT4051710T (lt) | 2019-10-31 | 2026-03-10 | Incyte Corporation | Priešnavikinė kompleksinė terapija, apimanti anti-cd19 antikūną ir gama delta ląsteles |
| TW202131950A (zh) | 2019-10-31 | 2021-09-01 | 德商莫菲西斯公司 | 依序抗ｃｄ１９療法 |
| WO2021084062A1 (en) | 2019-10-31 | 2021-05-06 | Morphosys Ag | Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma |
| EP4168449A1 (en) | 2020-06-22 | 2023-04-26 | MorphoSys AG | Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirpa-cd47 innate immune checkpoint |
| AU2021391623A1 (en) | 2020-12-04 | 2023-06-29 | Incyte Corporation | Anti-cd19 combination therapy |
| US20230357392A1 (en) | 2021-12-22 | 2023-11-09 | Morphosys Ag | Treatment Paradigm for an Anti-CD19 Antibody Therapy |
-
2017
- 2017-05-30 ES ES21170716T patent/ES2981046T3/es active Active
- 2017-05-30 SM SM20210291T patent/SMT202100291T1/it unknown
- 2017-05-30 WO PCT/EP2017/063045 patent/WO2017207574A1/en not_active Ceased
- 2017-05-30 MA MA45124A patent/MA45124B1/fr unknown
- 2017-05-30 JP JP2018562324A patent/JP7066639B2/ja active Active
- 2017-05-30 LT LTEP17728484.1T patent/LT3465214T/lt unknown
- 2017-05-30 FI FIEP21170716.1T patent/FI3916392T3/fi active
- 2017-05-30 LT LTEP21170716.1T patent/LT3916392T/lt unknown
- 2017-05-30 HR HRP20210938TT patent/HRP20210938T1/hr unknown
- 2017-05-30 SI SI201731527T patent/SI3916392T1/sl unknown
- 2017-05-30 MA MA57021A patent/MA57021B1/fr unknown
- 2017-05-30 MD MDE20190405T patent/MD3465214T2/ro unknown
- 2017-05-30 PL PL17728484T patent/PL3465214T3/pl unknown
- 2017-05-30 DK DK17728484.1T patent/DK3465214T3/da active
- 2017-05-30 DK DK21170716.1T patent/DK3916392T3/da active
- 2017-05-30 SG SG10201911958SA patent/SG10201911958SA/en unknown
- 2017-05-30 RS RS20210893A patent/RS62155B1/sr unknown
- 2017-05-30 EA EA201892542A patent/EA201892542A1/ru unknown
- 2017-05-30 PL PL21170716.1T patent/PL3916392T3/pl unknown
- 2017-05-30 EP EP17728484.1A patent/EP3465214B1/en active Active
- 2017-05-30 MD MDE20220770T patent/MD3916392T2/ro unknown
- 2017-05-30 CN CN202211271570.5A patent/CN115932265B/zh active Active
- 2017-05-30 MX MX2018014702A patent/MX388502B/es unknown
- 2017-05-30 SG SG11201810159TA patent/SG11201810159TA/en unknown
- 2017-05-30 RS RS20240525A patent/RS65540B1/sr unknown
- 2017-05-30 CN CN201780033793.9A patent/CN109313194B/zh active Active
- 2017-05-30 HU HUE17728484A patent/HUE054860T2/hu unknown
- 2017-05-30 PT PT177284841T patent/PT3465214T/pt unknown
- 2017-05-30 SI SI201730823T patent/SI3465214T1/sl unknown
- 2017-05-30 EP EP21170716.1A patent/EP3916392B1/en active Active
- 2017-05-30 IL IL263103A patent/IL263103B2/en unknown
- 2017-05-30 US US16/305,482 patent/US20190195879A1/en not_active Abandoned
- 2017-05-30 HR HRP20240670TT patent/HRP20240670T1/hr unknown
- 2017-05-30 AU AU2017272608A patent/AU2017272608B2/en active Active
- 2017-05-30 SM SM20240204T patent/SMT202400204T1/it unknown
- 2017-05-30 HU HUE21170716A patent/HUE067450T2/hu unknown
- 2017-05-30 KR KR1020187038026A patent/KR102416144B1/ko active Active
- 2017-05-30 PT PT211707161T patent/PT3916392T/pt unknown
- 2017-05-30 ES ES17728484T patent/ES2878156T3/es active Active
-
2018
- 2018-11-28 MX MX2021014963A patent/MX2021014963A/es unknown
- 2018-12-20 ZA ZA2018/08647A patent/ZA201808647B/en unknown
-
2021
- 2021-01-15 ZA ZA2021/00296A patent/ZA202100296B/en unknown
- 2021-07-13 CY CY20211100629T patent/CY1124768T1/el unknown
-
2022
- 2022-04-27 JP JP2022072884A patent/JP7511806B2/ja active Active
- 2022-05-25 US US17/824,266 patent/US12631639B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3916392T3 (da) | Fremgangsmåder til at forudsige terapeutiske fordele af anti-CD19-behandlingen hos patienter | |
| PL3600309T3 (pl) | Skojarzenia terapeutyczne do leczenia chorób wątroby | |
| DK3212233T3 (da) | Kombinationsterapi til behandling af sygdom | |
| IL255312A0 (en) | Therapeutic and diagnostic methods for cancer | |
| DK3347030T3 (da) | Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme | |
| DK3240612T3 (da) | Fremgangsmåder til behandling af nethindesygdomme | |
| HUE059662T2 (hu) | Eljárás terápiás immunsejtek hatékonyságának fokozására | |
| DK3024497T3 (da) | Fremgangsmåder og præparater til behandling af hjernesygdomme | |
| DK3450553T3 (da) | Mrna-terapi til behandling af øjensygdomme | |
| DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
| DK3485890T3 (da) | Sglt2-hæmmere til behandling af stofskifteforstyrrelser hos hundedyr | |
| DK3149049T3 (da) | Il-22 til anvendelse til behandling af stofskiftesygdomme | |
| DK3265087T3 (da) | Fremgangsmåde til behandling med tradipitant | |
| DK3151851T3 (da) | Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af komplement-medierede sygdomme hos patienter med c5-polymorfisme | |
| IL257355B (en) | Selection of patients for combination therapy | |
| DK3408265T3 (da) | Terapeutiske forbindelser | |
| DK3556383T5 (da) | Plasminogen til anvendelse ved behandling af diabetes | |
| HUE053648T2 (hu) | Gyógyászati kombinációk rák kezelésére | |
| DK3578562T3 (da) | L-valinatamidbenzoxaborolderivater til behandling af parasitiske sygdomme | |
| HUE063820T2 (hu) | Módszerek kardiovaszkuláris betegségek kezelésére | |
| DK3229827T3 (da) | Modificerede peptider og anvendelse deraf til behandling af kroniske inflammatoriske sygdomme | |
| DK3096775T3 (da) | SOCS-mimetika til behandling af sygdomme | |
| EP3518957C0 (en) | Therapeutic protein | |
| IL259381B (en) | Mirabegron for the treatment of retinal diseases | |
| DK3518801T3 (da) | System til kirurgisk behandling |